journal article·2024-10

Fe/Al‐LDH Nanomedicine for Antitumor Ferroptosis‐Immunotherapy by Immunosuppression Reversal

Wenming Fang, Zhiguo Yu, Ping Hu, Jianlin Shi

Advanced Functional Materials· Volume 34· Issue 44
Publisher page

Abstract

Abstract Ferroptosis is recognized as a novel type of programmed cell death with efficient immunogenicity to activate T cell‐mediated adaptive immune responses. However, conventional ferroptosis‐inducers mostly show poor efficacies due to their less effectiveness in immune regulation. In addition, suppression of T cells by M2‐type macrophages within the tumor microenvironment further weaken the immunotherapeutic effect of ferroptosis. To overcome these challenges, herein, an extremely simple Fe/Al‐layered double hydroxide (Fe/Al‐LDH) nanomedicine of enhanced iron concentration is reported, which is capable of selective degradation in acidic microenvironments to induce tumor cell ferroptosis and in the meantime reversing the immunosuppressive microenvironment by utilizing tumor cell ferroptosis and macrophage M1 polarization to synergistically enhance T cell immune response. This combined strategy has achieved excellent therapeutic efficacy in an orthotopic bilateral breast cancer model, demonstrating the great application potential of Fe/Al‐layered double hydroxide nanoplatform for iron ions‐regulated cancer immunotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Pneumocystis jirovecii pneumonia detection and treatment · Peptidase Inhibition and Analysis · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shanghai Institute of Ceramics Chinese Academy of Sciences Research Unit of Nanocatalytic Medicine in Specific Therapy for Serious Disease Chinese Academy of Medical Sciences Shanghai 200050 P. R. China

Center of Materials Science and Optoelectronics Engineering University of Chinese Academy of Sciences Beijing 100049 P. R. China

State Key Laboratory of Silicon and Advanced Semiconductor Materials and School of Materials Science and Engineering Zhejiang University Hangzhou 310027 P. R. China

Shanghai Tenth People's Hospital Shanghai Frontiers Science Center of Nanocatalytic Medicine School of Medicine Tongji University Shanghai 200331 P. R. China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Chinese Academy of Sciences

References (50)

Show source-provided references
1. 10.1016/j.cell.2012.03.04210.1016/j.cell.2012.03.042 ↗
2. 10.1073/pnas.160324411310.1073/pnas.1603244113 ↗
3. Wang W. J. · Angew. Chem., Int. Ed. · 2022 · 61 · 10
4. 10.1016/j.biomaterials.2021.12131510.1016/j.biomaterials.2021.121315 ↗
5. 10.1002/anie.20190488010.1002/anie.201904880 ↗
6. 10.1136/jitc-2020-00136910.1136/jitc-2020-001369 ↗
7. 10.1111/odi.1407710.1111/odi.14077 ↗
8. Chen Q. J. · Adv. Sci. · 2019 · 6 · 10
9. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
10. Dai X. M. · Adv. Mater. · 2023 · 35 · 12
11. 10.1016/j.biomaterials.2022.12193610.1016/j.biomaterials.2022.121936 ↗
12. 10.1002/bmm2.1202210.1002/bmm2.12022 ↗
13. Shen Z. Y. · Adv. Mater. · 2018 · 30 · 15
14. 10.1038/s41419-020-02939-310.1038/s41419-020-02939-3 ↗
15. Liu Q. L. · Regener. Biomater. · 2023 · 10 · 27
16. Song R. D. · Adv. Mater. · 2021 · 33 · 11
17. 10.1038/s41467-019-13790-210.1038/s41467-019-13790-2 ↗
18. 10.1038/ni.203510.1038/ni.2035 ↗
19. 10.1158/1078-0432.CCR-14-186010.1158/1078-0432.CCR-14-1860 ↗
20. 10.1016/j.immuni.2014.06.01010.1016/j.immuni.2014.06.010 ↗
21. Pittet M. J. · 2014 · 1
22. 10.1016/j.ccr.2013.02.01310.1016/j.ccr.2013.02.013 ↗
23. 10.12703/P6-1310.12703/P6-13 ↗
24. 10.1016/S1471-4906(02)02302-510.1016/S1471-4906(02)02302-5 ↗
25. 10.1016/j.ccell.2014.09.00610.1016/j.ccell.2014.09.006 ↗
26. 10.1038/nature2550110.1038/nature25501 ↗
27. 10.1038/nnano.2016.16810.1038/nnano.2016.168 ↗
28. 10.1002/bmm2.1203910.1002/bmm2.12039 ↗
29. 10.1021/jacs.8b1090410.1021/jacs.8b10904 ↗
30. 10.1016/j.chempr.2020.06.01310.1016/j.chempr.2020.06.013 ↗
31. Cao Z. B. · Adv. Sci. · 2018 · 5 · 10
32. 10.1021/acsami.9b1129110.1021/acsami.9b11291 ↗
33. 10.1002/anie.20151003110.1002/anie.201510031 ↗
34. 10.1016/j.biomaterials.2018.02.01810.1016/j.biomaterials.2018.02.018 ↗
35. 10.1002/bmm2.1201010.1002/bmm2.12010 ↗
36. 10.1016/S1572-1000(05)00097-910.1016/S1572-1000(05)00097-9 ↗
37. 10.1016/j.cell.2013.12.01010.1016/j.cell.2013.12.010 ↗
38. 10.1038/s41586-019-1170-y10.1038/s41586-019-1170-y ↗
39. 10.1016/j.ccell.2019.04.00210.1016/j.ccell.2019.04.002 ↗
40. 10.1146/annurev.immunol.18.1.76710.1146/annurev.immunol.18.1.767 ↗
41. 10.1021/jacs.1c0747110.1021/jacs.1c07471 ↗
42. 10.1038/s41467-022-35186-510.1038/s41467-022-35186-5 ↗
43. 10.1038/s41565-020-00781-410.1038/s41565-020-00781-4 ↗
44. 10.1002/cam4.167010.1002/cam4.1670 ↗
45. 10.1172/JCI5964310.1172/JCI59643 ↗
46. Wang S. · Small · 2022 · 18 · 13
47. 10.1038/s41467-018-07951-y10.1038/s41467-018-07951-y ↗
48. Wu C. Y. · Sci. Adv. · 2021 · 7 · 11
49. 10.1002/ijc.2542910.1002/ijc.25429 ↗
50. 10.1146/annurev.immunol.15.1.74910.1146/annurev.immunol.15.1.749 ↗